Capsulin OAD is under clinical development by Diabetology (Products) and currently in Phase II for Type 2 Diabetes. According to GlobalData, Phase II drugs for Type 2 Diabetes have a 37% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Capsulin OAD’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Capsulin OAD overview
Capsulin OAD (oral anti-diabetic) is under development for the treatment of type 2 diabetes. It is an oral encapsulated formulation of recombinant human insulin which acts by targeting insulin receptor. It is developed based on Axcess drug delivery technology.
Diabetology (Products) overview
Diabetology (Products) (Diabetology), a subsidiary of Proxima Concepts Ltd, is a biopharmaceutical company that develops oral drugs for the treatment of diabetes. The company provides oral delivery system to administer bioactives and compounds to transform the treatment outcomes for patients with diabetes. Its pipeline products include capsulin OAD, capsulin IR, oral GLP-1 analogue and combulin. Diabetology offers axcess, a system that increases the absorption of peptides, proteins and other macromolecules. Its capsulin OAD is an oral anti-diabetic used in the treatment of type 2 diabetes mellitus and oral GLP-1 analogue reduces glucose output from the liver and improves insulin sensitivity and the function of beta-cells. The company has operations in the UK and Australia. Diabetology is headquartered in Jersey, the UK.
For a complete picture of Capsulin OAD’s drug-specific PTSR and LoA scores, buy the report here.